Imagine your immune system is like a security team that has started attacking your own home by mistake. Instead of firing the whole team, which leaves the house open to burglars, this technology teaches the guards to recognize the home as safe again. It uses tiny particles grown in plants to deliver a specific message that stops the attack without disabling the overall defense system.
Current autoimmune treatments rely on general immunosuppression, which causes harmful side effects and fails to cure the disease. There is a critical need for therapies that restore self-tolerance without compromising the overall immune system.
A scalable GMP-ready production process for virus nanoparticles and a Quality Management System with 12 SOPs.
If you are a drug development firm dealing with the high side-effect profile of general immunosuppressants — this project developed virus nanoparticles that restore self-tolerance. This allows the body to fight the disease while maintaining the ability to defend against foreign threats.
If you are a producer dealing with inefficient protein expression — this project developed a Plant Molecular Farming Platform. It has already demonstrated a fivefold increase in downstream production yield for specific nanoparticles.
If you are a clinic dealing with chronic Rheumatoid Arthritis patients who lack a cure — this project developed a therapy that showed complete remission of symptoms in animal models. It offers a path toward a cure rather than just symptom management.
Based on available project data, specific pricing or cost-per-dose information is not provided; however, the project received an EU contribution of EUR 2,499,999 for development.
Yes, the project has optimized downstream production to be easily scalable and has redesigned facility layouts to align with GMP regulations for manufacturing.
The project utilizes a proprietary Plant Molecular Farming Platform and patented protected virus nanoparticles (VNPs).
The company has recruited a Qualified Person and QA Manager and implemented 12 SOPs to meet GMP standards and regulatory requirements for clinical testing.
The project period is from 2025-01-01 to 2026-12-31, focusing on pursuing clinical testing.
The project is led by a single Italian SME, DIAMANTE SOCIETA BENEFIT S.R.L, representing a 100% industry ratio. This lean structure suggests a fast-track approach to commercialization, focusing on the company's own proprietary platform without the complexity of academic partners.
Contact DIAMANTE SOCIETA BENEFIT S.R.L in Italy
Contact us to explore licensing opportunities for the Plant Molecular Farming Platform.
